As of November 6, 2026, abrdn Life Sciences Investors is a publicly traded company (NYSE: HQL); its largest reported holder is First Trust Portfolios L.P., with 11.34% on Schedule 13G/A of October 14, 2026. The largest insider holding is Boaz Weinstein, a 10% owner, with 2,968,623 shares held indirectly through a -, per Form 4 of September 4, 2025 (Schedule 13G/A, October 14, 2026).
Is this your company?
About to sign with, pay or invest in abrdn Life Sciences Investors? See the free Snapshot first.
Free to see. No signup.
Is abrdn Life Sciences Investors a real, registered company?
- abrdn Life Sciences Investors files with the SEC under CIK 884121 (its SEC filings).
- Its shares are listed under the ticker HQL on NYSE (SEC company record).
- Incorporated in Massachusetts; business address in Philadelphia, Pennsylvania, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under abrdn Life Sciences Investors in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names First Trust Portfolios L.P. (filed 2026-10-14).
Who are abrdn Life Sciences Investors' owners and officers?
abrdn Life Sciences Investors: incorporated in Massachusetts; business address in Philadelphia, Pennsylvania (Schedule 13G/A, 2026-10-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-14 | First Trust Portfolios L.P. | 11.34% |
| Schedule 13G/A, 2026-03-06 | First Trust Portfolios L.P. | 10.09% |
| Schedule 13D/A, 2026-02-23 | Saba Capital Management, L.P. | 4.95% |
| Schedule 13D/A, 2026-02-11 | Saba Capital Management, L.P. | 5.7% |
| Schedule 13D/A, 2026-01-08 | Saba Capital Management, L.P. | 6.77% |
| Schedule 13D/A, 2025-11-24 | Saba Capital Management, L.P. | 7.88% |
| Schedule 13D/A, 2025-09-26 | Saba Capital Management, L.P. | 8.96% |
| Schedule 13D/A, 2025-09-03 | Saba Capital Management, L.P. | 10.33% |
Questions about who owns abrdn Life Sciences Investors
Who owns abrdn Life Sciences Investors?
On this page, one holder's latest ownership filing reports 5% or more of abrdn Life Sciences Investors: First Trust Portfolios L.P. (11.34%, Schedule 13G/A, filed 2026-10-14).
When did First Trust Portfolios L.P. buy into abrdn Life Sciences Investors?
The filings give report dates, not purchase dates. The earliest filing from First Trust Portfolios L.P. on this page is the Schedule 13G/A, filed 2026-03-06, reporting 10.09%; its latest, Schedule 13G/A filed 2026-10-14, reports 11.34%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on abrdn Life Sciences Investors?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on abrdn Life Sciences Investors: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on abrdn Life Sciences Investors covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own abrdn Life Sciences Investors shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 2,968,623 shares, held indirectly through a -, on a joint filing (Form 4, 2025-09-04).
- Saba Capital Management, L.P., a 10% owner: 2,837,633 shares, held indirectly through a - (Form 4, 2025-09-23).
- , a director: 7,923 shares (Form 4, 2025-12-18).
- , a director: 527 shares (Form 4, 2026-07-20).
Shares only: the company's cover page does not give one share count for a single class, so no percentage is worked out.
How much has abrdn Life Sciences Investors raised?
No fundraising or offering filing from abrdn Life Sciences Investors is on file with us.
Keep reading
More on abrdn Life Sciences Investors and the records around it.
abrdn Life Sciences Investors elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Saba Capital Management, L.P. also filed stake reports on 69 other companies: BlackRock TCP Capital Corp. (Nov 2026), Ellsworth Growth and Income Fund Ltd. (Nov 2026), Virtus Total Return Fund Inc. (Nov 2026)
- First Trust Portfolios L.P. also filed stake reports on 105 other companies: First Trust Exchange-Traded Fund (Nov 2026), First Trust Exchange-Traded Fund IV (Nov 2026), First Trust Exchange-Traded Fund VIII (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/abrdn-life-sciences-investors